New Study: Active Ingredient Enhances Epigenetic Antitumor Responses

A research team including Thomas Carell has shown that the experimental compound cAzadC increases the expression of the epigenetic regulator TET2 and DNA hydroxymethylation. In patient-derived mouse models of acute myeloid leukemia, the treatment demonstrated improved antitumor activity. The study, which received co-funding from TRR237, was published in *Angewandte Chemie International Edition *. https://onlinelibrary.wiley.com/doi/full/10.1002/anie.6265286